|
|
[No.14905]
hUixnfxNVOWslumoa
I'm happy very good site fematril Pfizer Inc became an industry trendsetter in aggressive cost-cutting in early 2011 when it announced plans to chop annual research spending by as much as $3 billion. It went on to close numerous research sites and has halted or curtailed spending for research on drugs for allergy, urology, internal medicine and other therapeutic areas requiring large sales forces.
|
|